Vertex in long-term reimbursement agreement with ROI for CF medicines
Vertex Pharmaceuticals has reached an agreement with ROI to fund Orkambi for all of the approximately 500 people in Ireland with cystic fibrosis...
List view / Grid view
News
Global study sets new standard to personalise chemotherapy
In an analysis of 6 clinical trials with over 12,800 patients, 3 months of chemotherapy was nearly as effective as 6 months and caused fewer side effects...
Lynparza significantly reduces risk of disease worsening or death
8 June 2017 | By Niamh Marriott, Junior Editor
AstraZeneca's positive results from its trial that showed a statistically-significant and clinically-meaningful improvement in progression-free survival...
Novartis & Bristol-Myers Squibb to collaborate on cancer treatments
7 June 2017 | By Niamh Marriott, Junior Editor
Novartis has entered into a research collaboration in which Bristol-Myers Squibb will investigate the safety, tolerability, and efficacy of Mekinist...
Costs for generic hepatitis C drugs in India paid back in 5 years
7 June 2017 | By Niamh Marriott, Junior Editor
Treatment with generic directly-acting antiviral drugs available in India increases lifespan while reducing lifetime health care costs
Biosimilar trastuzumab candidate shown similar in efficacy and safety
7 June 2017 | By Niamh Marriott, Junior Editor
Data has shown similarity in efficacy and safety between CT-P6 (biosimilar trastuzumab candidate) and reference trastuzumab treatment in patients...
Hands-on lateral flow test development workshop
6 June 2017 | By BBI Solutions
BBI Solutions, in partnership with Merck and Kinematic Automation, is hosting a lateral flow seminar designed to provide a practical insight into lateral flow test development...
ViiV Healthcare submits regulatory applications for HIV two-drug regimen
6 June 2017 | By Niamh Marriott, Junior Editor
Regulatory submissions to the EMA and FDA for a single-tablet, two-drug regimen of dolutegravir & rilpivirine for the maintenance treatment of HIV...
FDA approves Roche’s lung cancer companion diagnostic
6 June 2017 | By Niamh Marriott, Junior Editor
The FDA have approved Roche’s VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients...
Sanofi and Boehringer Ingelheim confirm closing of business swap date
6 June 2017 | By Niamh Marriott, Junior Editor
The strategic transaction, which consists of an exchange of Sanofi's animal health business & Boehringer Ingelheim's CHC business, has been closed in market
Saratha Rajeswaran joins ABPI as Executive Director
2 June 2017 | By Niamh Marriott, Junior Editor
Sara Rajeswaran has joined the Association of the British Pharmaceutical Industry as the new Executive Director of Government Affairs and Devolved Nations.
ESMO welcomes the adoption of the 2017 WHO Cancer Resolution
2 June 2017 | By Niamh Marriott, Junior Editor
ESMO welcomes the adoption of cancer resolution on prevention and control in the context of an integrated approach during the 70th World Health Assembly...
EMA to review Sandoz biosimilars adalimumab and infliximab
Sandoz announced that the EMA has accepted for regulatory review for biosimilars to AbbVie's Humira (adalimumab) and Janssen's Remicade (infliximab)...
First treatment for 5q spinal muscular atrophy approved by EU
1 June 2017 | By Niamh Marriott, Junior Editor
The EC has granted marketing authorisation for Ionis Pharmaceuticals’ Spinraza (nusinersen) for the treatment of 5q spinal muscular atrophy (SMA)...
Aptar Pharma’s electronic lockout device approved by EMA
1 June 2017 | By Niamh Marriott, Junior Editor
The European Medicines Agency (EMA) has approved Aptar Pharma’s integrated electronic nasal lockout device (e-Lockout) following a partnership with Takeda.
